Kevin Becker, MD

Articles by Kevin Becker, MD

Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors

ByBenjamin P. Levy, MD,Parth Rao, MD,Daniel J. Becker, MD,Kevin Becker, MD

July 16th 2016

In this article, we review the available literature addressing the competing treatment strategies in EGFR-Positive Lung Cancer and attempt to clarify best treatment practices, including the emerging role of T790M-directed therapies.

Latest Updated Articles

Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors
July 16th 2016

Kevin Becker, MD

Articles by Kevin Becker, MD

Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors

Latest Updated Articles

Trending on CancerNetwork

TERN-701 Earns FDA Breakthrough Therapy Designation in Ph+ CML

Duvelisib Shows Significant Activity in R/R Peripheral T-Cell Lymphoma

ASCO Releases New Patient-Clinician Communication Guidelines

In Vivo CAR Engineering and the Next Phase of Cellular Immunotherapy

Melanoma Vaccine Receives FDA Fast Track Designation